Knowledge and intention to participate in cervical cancer screening after the human papillomavirus vaccine

Rebecca Anhang Price, Jill Koshiol, Sarah Kobrin, Jasmin A. Tiro

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: If women who receive the human papillomavirus (HPV) vaccine are unduly reassured about the cancer prevention benefits of vaccination, they may choose not to participate in screening, thereby increasing their risk for cervical cancer. This study assesses adult women's knowledge of the need to continue cervical cancer screening after HPV vaccination, describes Pap test intentions of vaccinated young adult women, and evaluates whether knowledge and intentions differ across groups at greatest risk for cervical cancer. Methods: Data were from the 2008 Health Information National Trends Survey (HINTS) and the 2008 National Health Interview Survey (NHIS), which initiated data collection approximately 18 months after the first FDA approval of an HPV vaccine. We calculated associations between independent variables and the outcomes using chi-square tests. Results: Of 1586 female HINTS respondents ages 18 through 74, 95.6% knew that HPV-vaccinated women should continue to receive Pap tests. This knowledge did not vary significantly by race/ethnicity, education, income, or healthcare access. Among 1101 female NHIS respondents ages 18-26 who had ever received a Pap test, the proportion (12.7%; n= 139) who reported receipt of the HPV vaccine were more likely than those not vaccinated to plan to receive a Pap test within three years (98.1% vs. 92.5%, p< 0.001). Conclusions: US adult women possess high knowledge and intention to participate in Pap testing after HPV vaccination. The vast majority of young adult women who received the HPV vaccine within its first two years on the market intend to participate in cervical cancer screening in the near future. Future studies are needed to examine whether those vaccinated in adolescence will become aware of, and adhere to, screening guidelines as they become eligible.

Original languageEnglish (US)
Pages (from-to)4238-4243
Number of pages6
JournalVaccine
Volume29
Issue number25
DOIs
StatePublished - Jun 6 2011

Fingerprint

Papillomavirus Vaccines
uterine cervical neoplasms
Papillomaviridae
Early Detection of Cancer
Uterine Cervical Neoplasms
Papanicolaou Test
vaccines
screening
Vaccination
health information
Health Surveys
vaccination
Young Adult
young adults
testing
interviews
Interviews
Health
Chi-Square Distribution
nationalities and ethnic groups

Keywords

  • Cancer screening
  • Cervical cancer
  • Disparities
  • Human papillomavirus (HPV)

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Knowledge and intention to participate in cervical cancer screening after the human papillomavirus vaccine. / Anhang Price, Rebecca; Koshiol, Jill; Kobrin, Sarah; Tiro, Jasmin A.

In: Vaccine, Vol. 29, No. 25, 06.06.2011, p. 4238-4243.

Research output: Contribution to journalArticle

Anhang Price, Rebecca ; Koshiol, Jill ; Kobrin, Sarah ; Tiro, Jasmin A. / Knowledge and intention to participate in cervical cancer screening after the human papillomavirus vaccine. In: Vaccine. 2011 ; Vol. 29, No. 25. pp. 4238-4243.
@article{8f714fc77d3e475fa1c4e6e3fe7dbe8b,
title = "Knowledge and intention to participate in cervical cancer screening after the human papillomavirus vaccine",
abstract = "Background: If women who receive the human papillomavirus (HPV) vaccine are unduly reassured about the cancer prevention benefits of vaccination, they may choose not to participate in screening, thereby increasing their risk for cervical cancer. This study assesses adult women's knowledge of the need to continue cervical cancer screening after HPV vaccination, describes Pap test intentions of vaccinated young adult women, and evaluates whether knowledge and intentions differ across groups at greatest risk for cervical cancer. Methods: Data were from the 2008 Health Information National Trends Survey (HINTS) and the 2008 National Health Interview Survey (NHIS), which initiated data collection approximately 18 months after the first FDA approval of an HPV vaccine. We calculated associations between independent variables and the outcomes using chi-square tests. Results: Of 1586 female HINTS respondents ages 18 through 74, 95.6{\%} knew that HPV-vaccinated women should continue to receive Pap tests. This knowledge did not vary significantly by race/ethnicity, education, income, or healthcare access. Among 1101 female NHIS respondents ages 18-26 who had ever received a Pap test, the proportion (12.7{\%}; n= 139) who reported receipt of the HPV vaccine were more likely than those not vaccinated to plan to receive a Pap test within three years (98.1{\%} vs. 92.5{\%}, p< 0.001). Conclusions: US adult women possess high knowledge and intention to participate in Pap testing after HPV vaccination. The vast majority of young adult women who received the HPV vaccine within its first two years on the market intend to participate in cervical cancer screening in the near future. Future studies are needed to examine whether those vaccinated in adolescence will become aware of, and adhere to, screening guidelines as they become eligible.",
keywords = "Cancer screening, Cervical cancer, Disparities, Human papillomavirus (HPV)",
author = "{Anhang Price}, Rebecca and Jill Koshiol and Sarah Kobrin and Tiro, {Jasmin A.}",
year = "2011",
month = "6",
day = "6",
doi = "10.1016/j.vaccine.2011.03.076",
language = "English (US)",
volume = "29",
pages = "4238--4243",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "25",

}

TY - JOUR

T1 - Knowledge and intention to participate in cervical cancer screening after the human papillomavirus vaccine

AU - Anhang Price, Rebecca

AU - Koshiol, Jill

AU - Kobrin, Sarah

AU - Tiro, Jasmin A.

PY - 2011/6/6

Y1 - 2011/6/6

N2 - Background: If women who receive the human papillomavirus (HPV) vaccine are unduly reassured about the cancer prevention benefits of vaccination, they may choose not to participate in screening, thereby increasing their risk for cervical cancer. This study assesses adult women's knowledge of the need to continue cervical cancer screening after HPV vaccination, describes Pap test intentions of vaccinated young adult women, and evaluates whether knowledge and intentions differ across groups at greatest risk for cervical cancer. Methods: Data were from the 2008 Health Information National Trends Survey (HINTS) and the 2008 National Health Interview Survey (NHIS), which initiated data collection approximately 18 months after the first FDA approval of an HPV vaccine. We calculated associations between independent variables and the outcomes using chi-square tests. Results: Of 1586 female HINTS respondents ages 18 through 74, 95.6% knew that HPV-vaccinated women should continue to receive Pap tests. This knowledge did not vary significantly by race/ethnicity, education, income, or healthcare access. Among 1101 female NHIS respondents ages 18-26 who had ever received a Pap test, the proportion (12.7%; n= 139) who reported receipt of the HPV vaccine were more likely than those not vaccinated to plan to receive a Pap test within three years (98.1% vs. 92.5%, p< 0.001). Conclusions: US adult women possess high knowledge and intention to participate in Pap testing after HPV vaccination. The vast majority of young adult women who received the HPV vaccine within its first two years on the market intend to participate in cervical cancer screening in the near future. Future studies are needed to examine whether those vaccinated in adolescence will become aware of, and adhere to, screening guidelines as they become eligible.

AB - Background: If women who receive the human papillomavirus (HPV) vaccine are unduly reassured about the cancer prevention benefits of vaccination, they may choose not to participate in screening, thereby increasing their risk for cervical cancer. This study assesses adult women's knowledge of the need to continue cervical cancer screening after HPV vaccination, describes Pap test intentions of vaccinated young adult women, and evaluates whether knowledge and intentions differ across groups at greatest risk for cervical cancer. Methods: Data were from the 2008 Health Information National Trends Survey (HINTS) and the 2008 National Health Interview Survey (NHIS), which initiated data collection approximately 18 months after the first FDA approval of an HPV vaccine. We calculated associations between independent variables and the outcomes using chi-square tests. Results: Of 1586 female HINTS respondents ages 18 through 74, 95.6% knew that HPV-vaccinated women should continue to receive Pap tests. This knowledge did not vary significantly by race/ethnicity, education, income, or healthcare access. Among 1101 female NHIS respondents ages 18-26 who had ever received a Pap test, the proportion (12.7%; n= 139) who reported receipt of the HPV vaccine were more likely than those not vaccinated to plan to receive a Pap test within three years (98.1% vs. 92.5%, p< 0.001). Conclusions: US adult women possess high knowledge and intention to participate in Pap testing after HPV vaccination. The vast majority of young adult women who received the HPV vaccine within its first two years on the market intend to participate in cervical cancer screening in the near future. Future studies are needed to examine whether those vaccinated in adolescence will become aware of, and adhere to, screening guidelines as they become eligible.

KW - Cancer screening

KW - Cervical cancer

KW - Disparities

KW - Human papillomavirus (HPV)

UR - http://www.scopus.com/inward/record.url?scp=79956205908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956205908&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.03.076

DO - 10.1016/j.vaccine.2011.03.076

M3 - Article

C2 - 21473953

AN - SCOPUS:79956205908

VL - 29

SP - 4238

EP - 4243

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 25

ER -